New approvals, rejections and studies across eye health, translated into what they mean for you. Every item links to its source, and we say plainly when something isn’t available yet.
Latest research
Retina and gene therapy
An optogenetic therapy for sight loss reaches FDA review
Under FDA review
The FDA accepted Nanoscope’s application for MOGENRY (MCO-010), a one-time injection that makes surviving retinal cells sensitive to light in people with retinitis pigmentosa and severe vision loss.
What it means for you. Most gene therapies fix one faulty gene. This one is designed to work regardless of which gene caused the disease, so if approved it could help far more people with inherited retinal disease. It is not approved yet.
What it means for you. A useful reminder that a positive headline from one trial isn’t the same as proof. If you see reproxalap promoted as a coming cure, it isn’t available in the US.
Yuvezzi, a combination of carbachol and brimonidine, was approved to treat presbyopia, the age-related loss of close-up focus.
What it means for you. It’s thought to work by narrowing the pupil, a pinhole effect that sharpens near vision for part of the day. In its trials the effect peaked in the first two hours, then faded. It’s an option for people who dislike readers, not a cure for aging eyes.
Low-dose atropine for kids’ myopia stalls in the US
Rejected; FDA panel review set
The FDA declined to approve SYD-101, a 0.01% atropine drop meant to slow worsening nearsightedness in children, even though its main trial met its goal. The FDA said the data didn’t support the drop’s effectiveness.
Update, September 2026: Sydnexis says the FDA has scheduled an advisory committee meeting, with a public hearing, for October 30, 2026 to review the drop’s application. It is still not approved in the US. Source: Sydnexis press release, September 2026 (opens in a new tab)
What it means for you. Low-dose atropine is approved in Europe and eye doctors in the US still prescribe compounded versions off-label. Ask your child’s eye doctor what they recommend.
Essilor Stellest became the first spectacle lens authorized in the US to slow myopia progression in children aged 6 to 12. In its US trial, it slowed progression by 71% over two years compared with regular lenses.
What it means for you. Until now, US families mainly had special contact lenses or off-label drops. Glasses are easier for many young kids.
The Tear Film & Ocular Surface Society published TFOS DEWS III, its third global report on dry eye. It defines dry eye as a disease that always comes with symptoms, and recommends diagnosing it with a short symptom questionnaire plus one measurable sign, such as a tear film that breaks up in under 10 seconds.
What it means for you. It confirms what patients have long said: how your eyes feel matters, even when the test results look mild.
A dry eye drop that helps your eyes make their own tears
FDA approved
Alcon’s Tryptyr (acoltremon) became the first approved dry eye drop to target TRPM8, the nerve receptor that senses cooling and helps trigger tearing.
What it means for you. Instead of adding artificial tears, it prompts your eyes to make more of their own, and in its trials the effect held through three months. It’s prescription only.
A meta-analysis of more than 300,000 people found each additional daily hour on screens was linked to 21% higher odds of myopia. Risk climbed most steeply between one and four hours a day.
What it means for you. It’s an association, not proof that screens cause myopia. Still, it supports keeping young children’s recreational screen time under an hour.
An AI model learns disease from 1.6 million eye scans
Research
Researchers published RETFound, an AI model trained on 1.6 million retinal images. It detected eye diseases and also predicted heart failure and heart attacks from photos of the back of the eye.
What it means for you. Your retina is the only place doctors can see blood vessels and nerves without cutting. Routine eye photos may one day flag body-wide disease early.
A Cochrane review of 17 trials found blue-light filtering lenses may make little or no difference to eye strain from computer use, at least in the short term.
What it means for you. If your eyes hurt after screen time, blinking, breaks and a proper eye exam are better bets than a filter.
Xdemvy (lotilaner) became the first drug approved for Demodex blepharitis, an overgrowth of tiny mites at the base of the lashes.
What it means for you. Crusty, dandruff-like debris on the lashes is a telltale sign. If you have it and lid scrubs haven’t helped, this is worth asking about.
Miebo (perfluorohexyloctane) was approved for dry eye. It forms a thin layer on the tear film that’s expected to slow evaporation, filling in for a weak oil layer.
What it means for you. Most dry eye is driven by evaporation, yet older prescription drops targeted inflammation or tear production. This one goes after the most common cause directly.
An intense pulsed light system from Lumenis became the first IPL device authorized in the US to improve signs of dry eye caused by meibomian gland dysfunction, used alongside gland expression.
What it means for you. IPL had been used off-label for years. Authorization, backed by a randomized controlled trial, made it a mainstream clinic option.
The DREAM trial gave 535 people with dry eye either 3,000 mg of omega-3 a day or an olive oil placebo for a year. Both groups improved by about the same amount.
What it means for you. It’s why we grade omega-3 supplements as mixed evidence and don’t make them a first step.
We focus on findings that change what patients can do or ask for: approvals, rejections, large trials and major reviews. Company press releases are useful for dates and facts, but we look for the underlying trial or regulatory document wherever we can, and we say when a result hasn’t been peer reviewed.
A single study rarely settles anything. When a new result changes the balance of evidence, we update the grades on our evidence board and note the date.
Get the radar by email
The Tear Sheet explains one new study each month, along with one thing worth trying.